Arcus Biosciences
RCUS · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$33.0M
Net margin
-1069.7%
ROE
-55.9%
Revenue CAGR (2y)
-5.6%
EPS (FY2025)
-3.29
Net profit (FY2025)
$-353.0M
Ask MarketChacha about RCUS
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 25, 2026
Arcus Biosciences shares rose with continued positive momentum in its oncology pipeline (notably Casdatifan in kidney cancer) and recent analyst target raises following the Q2 update, though no single new catalyst was reported for the session.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $33.0M | $-353.0M | -3.29 | -1069.7% | -55.9% |
| FY2024 | $51.0M | $-283.0M | -3.14 | -554.9% | -58.4% |
| FY2023 | $37.0M | $-307.0M | -4.15 | -829.7% | -66.5% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $33.0M | $-91.0M | -0.72 | -275.8% |
| 2026Q1 | $7.0M | $-128.0M | -1.02 | -1828.6% |
| 2025Q3 | $6.0M | $-135.0M | -1.27 | -2250.0% |
| 2025Q2 | $8.0M | $0 | 0.00 | 0.0% |
| 2025Q1 | $8.0M | $-112.0M | -1.14 | -1400.0% |
| 2024Q3 | $7.0M | $-92.0M | -1.00 | -1314.3% |
| 2024Q2 | $11.0M | $-93.0M | -1.02 | -845.5% |
| 2024Q1 | $10.0M | $-4.0M | -0.05 | -40.0% |
| 2023Q3 | $32.0M | $-71.0M | -0.94 | -221.9% |
| 2023Q2 | $29.0M | $-75.0M | -1.04 | -258.6% |
| 2023Q1 | $25.0M | $-80.0M | -1.09 | -320.0% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/5/2026material
- SEC8/5/2026
- SEC6/12/2026material
- SEC5/5/2026material
- SEC5/5/2026
- SEC4/20/2026material
- SEC3/23/2026material
- SEC2/25/2026material
- SEC2/25/2026
2025
- SEC12/18/2025material
- SEC12/12/2025material
- SEC11/3/2025material
- SEC10/28/2025material
- SEC10/28/2025
- SEC10/14/2025material
- SEC10/6/2025material
- SEC8/6/2025material
- SEC8/6/2025
In the news
- Arcus Biosciences (RCUS) Shares Rise on Promising Kidney Cancer Data from ARC-20 StudyGuruFocus · 10/20/2026
- Mizuho Optimistic on Arcus Biosciences (RCUS) After Casdatifan DGuruFocus · 10/20/2026
- Why is Arcus Biosciences stock sliding today?Investing.com · 10/20/2026
- Missed Arcus Biosciences' Rally? Here's What Early Buyers SawSimply Wall Street · 10/18/2026
- Arcus Biosciences (RCUS) And The Casdatifan Case As Fair Value Comes Into FocusSimply Wall Street · 10/16/2026
- William Blair initiates Arcus Biosciences stock with outperform rating By Investing.comInvesting.com Nigeria · 10/16/2026
- Two new hires at Arcus received rights to buy shares and awards tied to 4,600 sharesStock Titan · 10/9/2026
- Arcus Biosciences Drops 6.1% Amid Sector-Wide SellingAlphaStreet · 10/8/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.